Approval · Notice of Compliance 31116 · 2023
ESTROPLAN: Notice of Compliance 31116
Issued July 5, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31116
- Date
- July 5, 2023
- Company
- Parnell Technologies Pty LtdAlexandria, New South Wales, Australia
- Product type
- Veterinary
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Removal of the satement relating to the 24h-withdrawal period before slaughter
- Canadian reference product
- ESTRUMATE (Intervet Canada Corp)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESTROPLAN | 02298406 | Marketed |
Medicinal ingredients
- CLOPROSTENOL SODIUM 250 MCG per ML